Call for Expressions of Interest (EOI)
Australian Centre for HIV and Hepatitis Virology Research
Over the past 18 years, ACH2 has supported translational research in the areas of human
immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and now human T-lymphotropic virus type-1 (HTLV-1). In 2022, ACH2 will continue to support translational research into these four viral infections.
ACH2 is seeking expressions of interest (EOI) in applied research from qualified scientists to fund research projects aimed at: i) developing vaccine candidates for HIV, HBV subtypes, HCV or HTLV-1; ii) developing preventatives such as HIV microbicides and pre-exposure prophylaxis (PrEP); iii) cure and treatment interventions for HIV, HBV, or HTLV-1, including immunotherapy iv) novel diagnostics and prognostics for HIV, HBV, HCV, HTLV-1 or hepatitis B/C/HIV/HTLV-1 co-infection; v) molecular tools for tracking epidemics caused by these viruses; and vi) development of new tests for supporting vaccine and antiviral trials. Basic research is not eligible, and grants aimed at development of new direct-acting antivirals against HCV are also not eligible.
Administration Officer, ACH2
The Westmead Institute for Medical Research
PO Box 412
Westmead NSW 2145
Phone: (02) 8627 3004
Expressions of Interest close at 5:00 p.m. AEST on Monday 13 September 2021.